# 2025-08150: Microbial Nucleic Acid Detector Gets FDA Class II Designation

2025-08150, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microbial Nucleic Acids by Fluorescence In Situ Hybridization in Clinical Specimens, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-05-09, effective 2025-05-09; PRIA reads it as touching household money (as of 2026-10-16).

- Canonical: https://policyrisk.com/federal-register/2025-08150
- As of: 2026-10-16
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08150
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microbial Nucleic Acids by Fluorescence In Situ Hybridization in Clinical Specimens
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 19636
- Published: 2025-05-09
- Effective: 2025-05-09
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-16

## In one line

Microbial Nucleic Acid Detector Gets FDA Class II Designation

## Summary

The FDA is officially classifying a special device that detects and identifies tiny germs in patient samples using a cool glowing technique called FISH as a Class II device, meaning it’s safe and effective with some special rules. This change helps get these innovative tools to patients faster by cutting down red tape. The new rules took effect on May 9, 2025, and mainly affect companies making or using these devices in healthcare.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is classifying the device to detect and identify microbial nucleic acids by fluorescence in situ hybridization (FISH) in clinical specimens into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the device to detect and identify microbial nucleic acids by FISH in clinical specimens classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- FISH Microbial Test Moved to Class II: benefit, medium. The FDA officially classified devices that detect microbial nucleic acids by fluorescence in situ hybridization (FISH) in clinical specimens as Class II (special controls). This order is effective May 9, 2025, and the classification was applicable on August 18, 2017. The device is subject to premar…
- Required Design Verification and Validation Data: cost, medium. Manufacturers must provide detailed design verification and validation documentation to meet the special controls. Required items include device description, probe sequences and rationale, fluorophore and detection details, analytical studies (limit of detection, inclusivity, reproducibility, inter…
- Labeling Must Clarify Use and Limits: benefit, low. Device labeling must state the test is to be used along with clinical history, signs, symptoms, and other diagnostic tests. Labels must also explain how to interpret results and quality-control acceptance criteria, and must state that negative results do not rule out infection.
- De Novo Classification Enables Future 510(k) Predicates: benefit, medium. Because FDA classified this device into Class II via the De Novo process, the device can serve as a predicate for future devices, allowing later sponsors to use the 510(k) pathway rather than a De Novo request or premarket approval. The FDA notes this can reduce regulatory burdens and enhance patie…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08150 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/09/2025-08150/medical-devices-immunology-and-microbiology-devices-classification-of-the-device-to-detect-and)
- [2025-08150 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-09/pdf/2025-08150.pdf)

## Related
- [Previous: 2025-08149, Medical Devices; Immunology and Microbiology Devices; Classification of the Dev…](https://policyrisk.com/federal-register/2025-08149)
- [Next: 2025-08151, Medical Devices; Hematology and Pathology Devices; Classification of the Coagul…](https://policyrisk.com/federal-register/2025-08151)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08150 (as of 2026-10-16).
